CUA Educational Content

Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care


Fred Saad, Zineb Hamilou. Evan Weber

Michael Kolinsky, Jennifer Nuk, Alan So

Neil Fleshner, Urban Emmenegger, Emily Thain

The objective of this program is to provide health care providers with a review of genetic testing to guide treatment selection in metastatic prostate cancer and examine current and emerging evidence supporting the practical integration of PARP inhibitors into practice


  • Describe the significance and appropriate timing for testing for germline and somatic mutations in mCRPC
  • Evaluate the different modalities and avenues for testing
  • Review clinical safety and efficacy data for PARP inhibitors
  • Discuss the rationale for PARP inhibitor utilization in HRR-mutated mCRPC

  Ontario Edition  


  Western Canada Edition  


  Quebec/Atlantic Edition  



This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.


This program has received financial support from Merck and Astra Zeneca Canada.